Europe Hits Teva With €60M Fine Over Pay-For-Delay Deal
Europe's competition watchdog has slapped Israeli pharmaceutical giant Teva and its subsidiary Cephalon with more than €60 million (about $71 million) in fines for conspiring to keep a generic version of...To view the full article, register now.
Already a subscriber? Click here to view full article